JP7337060B2 - 安定なグルココルチコイド製剤 - Google Patents

安定なグルココルチコイド製剤 Download PDF

Info

Publication number
JP7337060B2
JP7337060B2 JP2020529561A JP2020529561A JP7337060B2 JP 7337060 B2 JP7337060 B2 JP 7337060B2 JP 2020529561 A JP2020529561 A JP 2020529561A JP 2020529561 A JP2020529561 A JP 2020529561A JP 7337060 B2 JP7337060 B2 JP 7337060B2
Authority
JP
Japan
Prior art keywords
formulation
less
months
dexamethasone
headspace
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020529561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514934A (ja
Inventor
テレサ デイシャー、
アダルバート ジャルジナ、
イアン ダンカン、
Original Assignee
エーブイエム・バイオテクノロジー・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーブイエム・バイオテクノロジー・エルエルシー filed Critical エーブイエム・バイオテクノロジー・エルエルシー
Publication of JP2021514934A publication Critical patent/JP2021514934A/ja
Priority to JP2023084640A priority Critical patent/JP2023116498A/ja
Application granted granted Critical
Publication of JP7337060B2 publication Critical patent/JP7337060B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020529561A 2018-11-14 2019-11-14 安定なグルココルチコイド製剤 Active JP7337060B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023084640A JP2023116498A (ja) 2018-11-14 2023-05-23 安定なグルココルチコイド製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767448P 2018-11-14 2018-11-14
US62/767,448 2018-11-14
PCT/US2019/061363 WO2020102474A1 (en) 2018-11-14 2019-11-14 Stable glucocorticoid formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023084640A Division JP2023116498A (ja) 2018-11-14 2023-05-23 安定なグルココルチコイド製剤

Publications (2)

Publication Number Publication Date
JP2021514934A JP2021514934A (ja) 2021-06-17
JP7337060B2 true JP7337060B2 (ja) 2023-09-01

Family

ID=68808595

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020529561A Active JP7337060B2 (ja) 2018-11-14 2019-11-14 安定なグルココルチコイド製剤
JP2023084640A Pending JP2023116498A (ja) 2018-11-14 2023-05-23 安定なグルココルチコイド製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023084640A Pending JP2023116498A (ja) 2018-11-14 2023-05-23 安定なグルココルチコイド製剤

Country Status (13)

Country Link
US (1) US20200289650A1 (enExample)
EP (1) EP3706721A1 (enExample)
JP (2) JP7337060B2 (enExample)
KR (2) KR102444113B1 (enExample)
CN (1) CN111918645A (enExample)
AU (1) AU2019378874B2 (enExample)
BR (1) BR112021009365A2 (enExample)
CA (1) CA3118505A1 (enExample)
EA (1) EA202191345A1 (enExample)
IL (1) IL283199A (enExample)
MX (1) MX2021005665A (enExample)
SG (1) SG11202104702VA (enExample)
WO (1) WO2020102474A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116789728A (zh) * 2023-06-16 2023-09-22 山东斯瑞药业有限公司 一种降低糖皮质激素原料药重金属元素杂质含量的工艺
CN116807970A (zh) * 2023-07-26 2023-09-29 遂成药业股份有限公司 一种地塞米松磷酸钠注射液及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502975A (ja) 1998-02-03 2002-01-29 バイエル コーポレイション ゼロヘッドスペース容器での安定ｐＯ２を有する多分析物参照溶液
JP2006136490A (ja) 2004-11-11 2006-06-01 Terumo Corp 塩酸リトドリン注射液製剤
JP2011136973A (ja) 2009-12-28 2011-07-14 Keiki Imoto 安定なエダラボン含有水性製剤
JP2014207983A (ja) 2013-03-28 2014-11-06 テルモ株式会社 アセトアミノフェン注射液製剤
JP2015042638A (ja) 2008-02-07 2015-03-05 アムジエン・インコーポレーテツド 安定化されたタンパク質組成物
JP2016518404A (ja) 2013-05-08 2016-06-23 シージェイ ヘルスケア コーポレイションＣｊ Ｈｅａｌｔｈｃａｒｅ Ｃｏｒｐｏｒａｔｉｏｎ 安定化したペメトレキセド製剤
WO2018183927A1 (en) 2017-04-01 2018-10-04 Avm Biotechnology, Llc Replacement of cytotoxic preconditioning before cellular immunotherapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
US9694103B2 (en) * 2003-04-16 2017-07-04 The Children's Hospital Of Philadelphia Photochemical activation of surfaces for attaching biomaterial
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
CN101340916A (zh) * 2005-12-22 2009-01-07 兴和株式会社 类固醇的经时稳定性得到改善的外用制剂
AU2013200089B2 (en) * 2006-02-09 2016-03-03 Santen Pharmaceutical Co., Ltd Stable formulations, and methods of their preparation and use
CN101623291B (zh) 2008-07-07 2011-12-07 天津金耀集团有限公司 一种地塞米松磷酸钠注射液
EP2365812A4 (en) * 2008-11-10 2012-05-16 Nitric Biotherapeutics Inc PHARMACEUTICAL FORMULATIONS FOR THE IONTOPHORETIC DELIVERY OF A CORTICOSTEROID
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
CA2844109C (en) 2010-08-18 2018-11-06 Theresa Deisher Compositions and methods to inhibit stem cell binding to active germinal centers in lymphatic tissues
ITMI20122002A1 (it) 2012-11-26 2014-05-27 Farmacologico Milanese Srl Lab Preparazioni farmaceutiche liquide stabilizzate
GR1008921B (el) 2015-12-10 2017-01-12 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δεξαμεθαζονη
CN107375200A (zh) 2017-06-16 2017-11-24 北京立时达药业有限公司 一种地塞米松磷酸钠注射液及其制备方法
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502975A (ja) 1998-02-03 2002-01-29 バイエル コーポレイション ゼロヘッドスペース容器での安定ｐＯ２を有する多分析物参照溶液
JP2006136490A (ja) 2004-11-11 2006-06-01 Terumo Corp 塩酸リトドリン注射液製剤
JP2015042638A (ja) 2008-02-07 2015-03-05 アムジエン・インコーポレーテツド 安定化されたタンパク質組成物
JP2011136973A (ja) 2009-12-28 2011-07-14 Keiki Imoto 安定なエダラボン含有水性製剤
JP2014207983A (ja) 2013-03-28 2014-11-06 テルモ株式会社 アセトアミノフェン注射液製剤
JP2016518404A (ja) 2013-05-08 2016-06-23 シージェイ ヘルスケア コーポレイションＣｊ Ｈｅａｌｔｈｃａｒｅ Ｃｏｒｐｏｒａｔｉｏｎ 安定化したペメトレキセド製剤
WO2018183927A1 (en) 2017-04-01 2018-10-04 Avm Biotechnology, Llc Replacement of cytotoxic preconditioning before cellular immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Otol Nerrol，2015年，36，1321-1327
Tetrahedron Letters，2009年，50(32)，4575-4581
医薬品インタビューフォーム ソルコート静注液１００ｍｇ，2011年

Also Published As

Publication number Publication date
BR112021009365A2 (pt) 2021-08-10
AU2019378874A1 (en) 2021-06-17
US20200289650A1 (en) 2020-09-17
EA202191345A1 (ru) 2021-10-08
IL283199A (en) 2021-06-30
JP2023116498A (ja) 2023-08-22
JP2021514934A (ja) 2021-06-17
CN111918645A (zh) 2020-11-10
MX2021005665A (es) 2021-09-23
CA3118505A1 (en) 2020-05-22
KR20220130253A (ko) 2022-09-26
AU2019378874B2 (en) 2025-05-29
KR20200111675A (ko) 2020-09-29
WO2020102474A1 (en) 2020-05-22
KR102444113B1 (ko) 2022-09-19
SG11202104702VA (en) 2021-06-29
EP3706721A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
US12310930B2 (en) Stabilization of epinephrine formulations
US20180028671A1 (en) Epinephrine formulations for medicinal products
US20120101169A1 (en) Methods of providing anticoagulation effects in subjects
US20070275089A1 (en) Argon-based inhalable gaseous medicinal product for the treatment of neurointoxications
JP2023116498A (ja) 安定なグルココルチコイド製剤
EP3193907B1 (en) Method of treating prader-willi syndrome
US11925608B2 (en) Stabilization of epinephrine formulations
CN110996910A (zh) 抑郁障碍的治疗
EP2735305A1 (en) Stabilised liquid pharmaceutical preparations
EP3579836B1 (en) Methods for autism spectrum disorder pharmacotherapy
US20230137790A1 (en) Stable injectable epinephrine formulations including a metal-chelating agent
EP3243510A1 (en) Sulfonamide pharmaceutical composition
AU2019326539A1 (en) Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
AU2015242374B2 (en) New use of N,N-bis-2-mercaptoethyl isophthalamide
US20240122883A1 (en) Methods of treating a subject exposed to a toxic inhaled chemical with mesna
EP3880168B1 (en) Aqueous paediatric retinol formulations
EP4637739A1 (en) Novel methods for treating gastroparesis
WO2024137814A1 (en) Reduction of healthcare resource utilization by patients treated with intranasally-administered metoclopramide
KR20250099117A (ko) 도파민을 포함하는 약학적 주사용액
WO2024214110A1 (en) A safe pharmaceutical composition of hydrocortisone
JP2005343846A (ja) アレルギー性鼻炎予防用医薬組成物
HK40027257A (en) Treatment of depressive disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230523

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230822

R150 Certificate of patent or registration of utility model

Ref document number: 7337060

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150